Abstract
It is known that breast and ovarian tumors with germline mutations in BRCA1 or BRCA2 genes are up to 1000 times more sensitive to treatment with PARP inhibitors than wild type tumors. Although, little is known about the effect of these PARP inhibitors on tumors harboring mutations in other genes involved in the homologous recombination mechanism of DNA repair. The objective of this work i…